Robert P Giugliano

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

Peter Lindgren, Yi Qian, Ben van Hout, 2017, JAMA cardiology.

A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation.

R. Giugliano, Robert P Giugliano, Ariel Dogliotti, 2015, European heart journal. Cardiovascular pharmacotherapy.

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.

Brian A Ference, R. Giugliano, M. Sabatine, 2016, JAMA.

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Alexander Parkhomenko, A. Parkhomenko, B. Lewis, 2014, The Lancet.

The P-glycoprotein transport system and cardiovascular drugs.

R. Giugliano, Robert P Giugliano, J. Mendell, 2013, Journal of the American College of Cardiology.

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Szilard Voros, Jennifer G. Robinson, Brian A Ference, 2016, The New England journal of medicine.

A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy

David A Morrow, E. Antman, R. Giugliano, 2001, The Lancet.

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48.

Deepak K Gupta, S. Solomon, E. Antman, 2014, European heart journal.

Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time.

R. Giugliano, E. Braunwald, Robert P Giugliano, 2003, Circulation.